比较氢化可的松低频与大剂量给药方案在感染性休克中的效果
该单中心回顾性队列研究纳入138例感染性休克成人患者,比较氢化可的松50 mg每6小时(61例)与100 mg每12小时(77例)两种方案。校正竞争风险模型显示,两组在休克缓解时间(亚HR 0.95,95%CI 0.59-1.54)、ICU死亡率(亚HR 1.59,95%CI 0.89-2.84)、院内死亡率(亚HR 1.35,95%CI 0.81-2.26)及肾替代治疗时间(亚HR 1.01,95%CI 0.45-2.31)均无显著差异。最大升压药剂量(去甲肾上腺素等效均值差0.16 µg/kg/min,95%CI -0.26至0.58 µg/kg/min)也无差异。低频给药每例节省446.10美元(95%CI 253.95-638.25)。作者认为需要进一步研究不同皮质类固醇给药方案在感染性休克中的比较效果。
要点
- 在感染性休克成人患者中,氢化可的松100 mg每12小时与50 mg每6小时相比,休克缓解时间无显著差异(亚HR 0.95,95%CI 0.59-1.54)。
- 两组ICU死亡率(亚HR 1.59,95%CI 0.89-2.84)和院内死亡率(亚HR 1.35,95%CI 0.81-2.26)均无显著差异。
- 两组肾替代治疗时间无显著差异(亚HR 1.01,95%CI 0.45-2.31),最大升压药剂量也无差异(去甲肾上腺素等效均值差0.16 µg/kg/min,95%CI -0.26至0.58 µg/kg/min)。
- 低频给药方案每例患者节省446.10美元(95%CI 253.95-638.25)。
- 作者认为需要进一步研究不同皮质类固醇给药方案在感染性休克中的比较效果。
适用人群与场景
- 成人感染性休克患者,定义为充分液体复苏后平均动脉压仍低于65 mm Hg且需要升压药输注,在2022年10月24日至2023年10月12日期间因休克接受氢化可的松治疗。
诊断标准与关键阈值
- 感染性休克定义:充分液体复苏后平均动脉压低于65 mm Hg,且需要升压药输注。
处置流程与药物剂量
- 氢化可的松50 mg每6小时或100 mg每12小时,用于感染性休克成人患者的休克辅助治疗。
研究设计与关键结果
- 单中心回顾性队列研究,纳入138例成人感染性休克患者,其中50 mg每6小时组61例,100 mg每12小时组77例。
- 校正竞争风险模型显示,氢化可的松方案与休克缓解时间无显著关联(亚HR 0.95,95%CI 0.59-1.54)。
- ICU死亡率亚HR 1.59(95%CI 0.89-2.84),院内死亡率亚HR 1.35(95%CI 0.81-2.26),肾替代治疗时间亚HR 1.01(95%CI 0.45-2.31),均无显著差异。
- 最大升压药剂量(去甲肾上腺素等效)均值差0.16 µg/kg/min(95%CI -0.26至0.58 µg/kg/min),无显著差异。
- 低频给药方案每例节省446.10美元(95%CI 253.95-638.25)。
证据类型、等级与局限
- 证据类型:单中心、回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在感染性休克成人患者中,氢化可的松100 mg每12小时与50 mg每6小时相比,休克缓解时间、死亡率、肾替代治疗及最大升压药剂量均无显著差异,且低频给药每例节省446.10美元。
- 作者认为需要进一步研究不同皮质类固醇给药方案在感染性休克中的比较效果。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Guidelines recommend hydrocortisone as an adjunctive treatment in septic shock, but the optimal dosing regimen is unknown. A national shortage of hydrocortisone in 2023 prompted a change in institutional practice for hydrocortisone administration from 50 mg every 6 hours to 100 mg every 12 hours in an effort to reduce waste and conserve vials, creating an opportunity to evaluate the comparative effectiveness of these two regimens. The primary efficacy outcome was time to shock resolution, and secondary outcomes evaluated in this study were mortality, renal replacement therapy (RRT), medication costs, and maximum vasopressor dose attained.
DESIGN: Single-center, retrospective cohort study.
SETTING: ICUs in a quaternary academic medical center.
PATIENTS: Adult patients admitted to an ICU with septic shock, defined by mean arterial pressure less than 65 mm Hg despite adequate fluid resuscitation and need for vasopressor infusion, who were treated with hydrocortisone for shock between October 24, 2022, and October 12, 2023.
INTERVENTIONS: Treatment with hydrocortisone 50 mg every 6 hours or 100 mg every 12 hours.
MEASUREMENTS AND MAIN RESULTS: One hundred thirty-eight patients were included in this retrospective chart review from October 24, 2022, to October 12, 2023. Data for 61 patients in the 50 mg every 6 hours group and 77 patients in the 100 mg every 12 hours group were collected and analyzed. In adjusted competing risk models, hydrocortisone regimen was not associated with differences in time to shock resolution (sub-hazard ratio [sub-HR] 0.95 [95% CI, 0.59-1.54]), ICU mortality (sub-HR 1.59; 95% CI, 0.89-2.84), in-hospital mortality (1.35; 95% CI, 0.81-2.26), or time to RRT (sub-HR 1.01; 95% CI, 0.45-2.31). In addition, the hydrocortisone dose regimen was not associated with differences in maximum vasopressor dose attained (mean difference in norepinephrine equivalent, 0.16 µg/kg/min; 95% CI, -0.26 to 0.58 µg/kg/min). The less frequent dosing resulted in cost savings of $446.10 (95% CI, 253.95-638.25) per patient treated with the more intensive but less frequent hydrocortisone dosing regimen.
CONCLUSIONS: A less frequent hydrocortisone dosing regimen was not associated with differences in time to shock resolution. Studies of the comparative effectiveness of different corticosteroid dosing regimens for septic shock are needed.
参考来源
- Hao A, Wu TD, Collins K, et al. Comparative Effectiveness of Less vs. More Frequent Hydrocortisone Dosing in Septic Shock. Crit Care Explor. 2025. PMID: 40953288. doi:10.1097/CCE.0000000000001316
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。